Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

21 Jun 2010

Arterial reconstruction in adult-to-adult LDLT has high risk of thrombosis: Study

Hepatic artery thrombosis, which is the most common vascular complication after living donor liver transplantation, can result in graft loss and devastating consequences. Surgical techniques are suggested to an important factor in causing HAT. Despite improvements in surgical techniques, arterial reconstruction in LDLT has a high risk of thrombosis.

21 Jun 2010

USFDA approves Sun Pharma's generic Xanax ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Xanax®, alprazolam tablets.

18 Jun 2010

Pelvic extraperitoneal IMT with malignant transformation in 14-year-old

Inflammatory myofibroblastic tumor (IMT) is an uncommon benign neoplasm with locally aggressive behavior but malignant change is rare. Such a rare tumor occurring in a 14-year-old patient with clinical presentations of abdominal pain and body weight loss was seldom described before.

18 Jun 2010

Blueberry consumption is beneficial for hepatic diseases: Study

Conventional drugs used in the treatment of liver diseases inevitably have side effects. An increasing number of natural substances have been studied to explore if they have protective effects on the liver. Blueberries have unique effects on human retinal, brain and tumor cells, but reports about the effects of blueberries on liver diseases are lacking.

18 Jun 2010

Neonatal diarrhea may lead to life threatening dehydration and malnutrition: Research

Diarrhea represents a major condition responsible for pediatric mortality worldwide. The onset of neonatal diarrhea may rapidly lead to life threatening dehydration and malnutrition. Clinical and epidemiologic studies defining severity and etiology are needed in order to improve diagnostic and therapeutic approaches for the management of neonatal diarrhea.

18 Jun 2010

Study evaluates effect of Viusid on oxidative stress, cytokine parameters in patients with CHC

The pathogenesis of chronic hepatitis C is associated with severe oxidative stress and non-selective immunological disturbance that lead to necroinflammation and the progression of fibrosis. Several trials have suggested that antioxidant and immunostimulant therapies may have a beneficial effect. Two previous clinical studies have reported that the Viusid related effect on histologic features, especially fibrosis, appears to be associated with antioxidant and/or immunomodulatory properties.

18 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Keppra® Injection, levetiracetam injection.

17 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

ASGE Endoscopy Unit Recognition Program honors 48 endoscopy units

The American Society for Gastrointestinal Endoscopy has recognized 48 endoscopy units as part of its program specifically dedicated to promoting quality in endoscopy, in all settings where it is practiced in the United States. The ASGE Endoscopy Unit Recognition Program honors endoscopy units that follow the ASGE guidelines on privileging, quality assurance, endoscopy reprocessing and CDC infection control guidelines.

15 Jun 2010

Intellipharmaceutics International files Protonix ANDA with FDA

Intellipharmaceutics International Inc. today announced that is has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic of Protonix® (delayed release pantoprazole sodium). Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.

14 Jun 2010

Interactions between human and microbial cells determine health, physical well-being: Researchers

At birth, your body was 100-percent human in terms of cells. At death, about 10-percent of the cells in your body will be human and the remaining 90-percent will be microorganisms. That makes you a "supraorganism," and it is the interactions between your human and microbial cells that go a long way towards determining your health and physical well-being, especially your resistance to infectious diseases.

11 Jun 2010

2010 GAPS sheds light on the painful reality of what life is like for gout patients

The 2010 Gout Attitudes Patient Survey, a new study of Americans with gout, released by Men's Health Network, sheds light on the painful reality of what life is like for the approximately five million Americans who live with this condition. Of those surveyed, 69 percent described the pain of a gout attack as "miserable," yet a quarter of gout patients feel that those without gout perceive them as overreacting to attacks, and 67 percent feel as though others do not take the condition seriously.

11 Jun 2010

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Further results from the European Survey of Breakthrough Cancer Pain were presented for the first time today at the 6th Research Congress of the European Association for Palliative Care in Glasgow.

11 Jun 2010

Sucampo announces completion of lubiprostone phase 3 trial for CIC in Japanese patients

Sucampo Pharmaceuticals, Inc. announced that phase 3 double blind trial of lubiprostone (marketed as AMITIZA (R) in the U.S.) for chronic idiopathic constipation in Japanese patients has been completed.

10 Jun 2010

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Arterial reconstruction in adult-to-adult LDLT has high risk of thrombosis: Study

USFDA approves Sun Pharma's generic Xanax ANDA

Pelvic extraperitoneal IMT with malignant transformation in 14-year-old

Blueberry consumption is beneficial for hepatic diseases: Study

Neonatal diarrhea may lead to life threatening dehydration and malnutrition: Research

Study evaluates effect of Viusid on oxidative stress, cytokine parameters in patients with CHC

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

ASGE Endoscopy Unit Recognition Program honors 48 endoscopy units

Intellipharmaceutics International files Protonix ANDA with FDA

Interactions between human and microbial cells determine health, physical well-being: Researchers

2010 GAPS sheds light on the painful reality of what life is like for gout patients

Inadequate treatment strategies make cancer patients suffer unnecessarily: Survey

Sucampo announces completion of lubiprostone phase 3 trial for CIC in Japanese patients

Your full guide to the gut microbiome eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Your full guide to the gut microbiome eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in